VivoSeq
Other

Peyronie's Disease

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Peyronie's Disease is an early-stage landscape with 0 programs across 1 company. The most active players are Endo Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Endo Pharmaceuticals logo

Endo Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Completed11 · 65%
Unknown status3 · 18%
Recruiting3 · 18%

Clinical Trials

Trial Activity

17 trials

Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
Recruiting·MMayo Clinic·N/A·NCT06065436·60 enrolled
Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease
Recruiting·CCharitable Union for the Research and Education of Peyronie's Disease·Phase 4·NCT06649539·40 enrolled
Comparative Outcomes of Subtunical Microdissection and Grafting Versus Classical Plaque Incision and Grafting in Complex Peyronie's Disease
Recruiting·NNamik Kemal University·Preclinical·NCT07470528·80 enrolled
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 2·NCT01430169·20 enrolled
H-22411: BOTOX® for Peyronie's Disease
Completed·—·Phase 2·NCT00812838·12 enrolled
The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 2·NCT00755222·147 enrolled
PRP for Treatment of Peyronie's Disease
Completed·UUniversity of Miami·Phase 2·NCT04512287·65 enrolled
Study of AA4500 in the Treatment of Peyronie's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT01221597·418 enrolled
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT01685437·189 enrolled
A Study of AA4500 in Men With Peyronie's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT01243411·348 enrolled
An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT02267460·30 enrolled
Peyronie's Disease Treatment Protocol
Completed·HHybrid Medical·Phase 1·NCT02072018·22 enrolled
Study of AA4500 in the Treatment of Peyronie's Disease
Completed·Endo Pharmaceuticals logoEndo Pharmaceuticals·Phase 3·NCT01221623·418 enrolled
Testosterone Pellets Plus Vitamin D and E Versus Vitamin D and E Alone for the Treatment of Peyronie's Disease
Completed·MMen's Health Boston·Phase 1·NCT01578473·75 enrolled
Management of Peyronie's Disease With Adipose Tissue Stem Cell
Unknown status·MMan Clinic for Andrology, Male Infertility and Sexual Dysfunction·N/A·NCT02414308·20 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)